Aquiring the Evidence TEACH 2013 TRACK 1
Therapy Utility Performance Likelihood Diagnosis Utility Performance Likelihood Prognosis Utility Performance Likelihood Harm Utility Performance Likelihood LINKING QUESTIONS TO STUDY DESIGNS RCT COHORT CROSS-SECTIONAL CASE CONTROL
THERAPY Utility Performance Likelihood DIAGNOSIS Utility Performance Likelihood PROGNOSIS Utility Performance Likelihood HARM Utility Performance Likelihood LINKING QUESTIONS TO STUDY DESIGNS THERAPY RCT Cohort DIAGNOSIS RCT Cross-Sectional Observational PROGNOSIS RCT Cohort Cohort/Single Arm HARM Cohort, Case-Control Cohort Cohort/Single Arm
LINKING STUDY DESIGNS TO SOURCES
EBM SEARCH ENGINES
QUESTION 1 Therapy/Utility P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset I: Rapid acting pharmacological agents safely titrated to effect C: Alternative regimens safely titrated to effect O: Likelihood of rate control or cardioversion, hospital admission, complications of uncontrolled AF, adverse reactions to drugs BACK TO THE CASE Practice Guidelines, Systematic Review, RCT, Non-randomized studies
QUESTION 2 Prognosis/Likelihood P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset I: Observation over a 30-day period C: N/A O: Stroke, decompensated heart failure, MI, death BACK TO THE CASE Practice Guidelines, Systematic Review, Cohort, Control Arm of an RCT
QUESTION 3 Harm/Likelihood P: Elderly patients with acute, stable AF, but no structural heart disease presenting to the ED < 48 hours of onset I: Cardioversion in ED with discharge and early follow-up C: N/A O: Short-term complications of cardioversion, embolic events, admission, other complications of AF BACK TO THE CASE Practice Guidelines, Systematic Review, Cohort, Single-Arm Study
SUMMARY: NGC, GIN Dynamed SYNTHESIS: DARE QUESTION 1
SYNTHESIS: Pubmed SINGLE STUDY: Pubmed QUESTION 2
QUESTION 3 SUMMARY: NGC SINGLE STUDY: Pubmed